[Corrections] Correction to Lancet Oncol 2024; 25: e126–35

Koole SN, Huisman AH, Timmers L, et al. Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications. Lancet Oncology 2024; 25: e126–35—In this Review, the abbreviation of “homologous recombination deficiency” should have been HRd throughout, and in the third paragraph of the Observations of withdrawals of drug approvals based on trials with surrogate primary endpoints section, the fifth sentence of this paragraph should have read “An unpowered analysis for patients with homologous recombination proficient tumours showed a median progression-free survival of 8·4 months in the niraparib group versus 5·4 months in the placebo group (HR 0·65, 95% CI 0·49–0·87)”.